A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

作者：Greenwald Daniel R^*; Li Hailun; Luger Selina M; Go Ronald S; King David; Patel Taral; Gascoyne Randy D; Kolesar Jill; Kahl Brad S; Horning Sandra

来源：Journal of Hematology & Oncology, 2013, 6: 46.

DOI：10.1186/1756-8722-6-46

• NHL
• Diffuse large B cell lymphoma
• MAP kinase signaling
• Sorafenib

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43-9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles administered was 3 (range, 1-12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90% CI, 0.4 - 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI, 1 - 5 months). Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.

• 出版日期2013-7-5